NEW YORK, July 31 - German text-mining software provider Definiens and genomics-tool maker Evotec Technologies will co-develop an informatics-based platform for cellular-assay analysis and drug discovery.
To facilitate the collaboration, designed to enable researchers to perform high throughput screening of assays in cell biology, Evotec will ensure that its Libretto software will be compatible with Definiens Cellenger platform. According to Definiens, the Challenger software enables researchers to perform automated tissue and cellular-assay analysis.
Evotec's confocal microplate analyzer for image detection, called Opera, will also be folded into the development project. "Cellenger further extends Opera's capabilities as an open platform for cell biology experimentation, and with our open software architecture we could implement this extension quickly" said Evotec CSO Rolf G nther.
Added Uli Berresheim, CEO of Definiens: "We are going to create a system that will automatically provide the user with valuable information about cells, cell components, and their mutual relations."
The companies expect to launch the platform by the end of September. Financial details of the deal were not disclosed.